Workboat Indexes

Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

303.27 +10.69 (+3.66%)

Streaming Delayed Price Updated: 12:36 PM EDT, Jun 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart ↗

January 21, 2022

If history is any guide, there may be trouble ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "death cross" has formed on its chart and, not surprisingly,...

Via Benzinga

Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited Disease ↗

January 21, 2022

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-...

Via Benzinga

The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective ↗

January 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura...

Via Benzinga

Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

January 21, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

January 20, 2022

Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:

Via Benzinga

The Week Ahead In Biotech (Jan. 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week ↗

January 16, 2022

Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Here are the key catalysts...

Via Talk Markets

The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week ↗

January 16, 2022

Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss...

Via Benzinga

The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗

January 13, 2022

Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?

Via Investor's Business Daily

Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting

January 14, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates

January 09, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function

January 06, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President

January 04, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

What 9 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

January 03, 2022

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:

Via Benzinga

Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference

January 03, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022 ↗

January 03, 2022

Upgrades For nVent Electric PLC (NYSE:NVT), Vertica...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates ↗

December 31, 2021

Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...

Via Benzinga

51 Biggest Movers From Yesterday ↗

December 28, 2021

Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

December 27, 2021

Gainers Microbot Medical (NASDAQ:MBOT) stock moved upwards by 47.87% to $8.02 during Monday's regular session. The current volume of 63.6 million shares is 153229.83%...

Via Benzinga

34 Stocks Moving In Monday's Mid-Day Session ↗

December 27, 2021

Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY...

Via Benzinga

BridgeBio Pharma Stock Crashes As Pfizer-Rivaling Heart Drug Flops ↗

December 27, 2021

Patients who received the drug didn't improve in the six-minute walking test.

Via Investor's Business Daily

FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol ↗

December 23, 2021

The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C). Leqvio is...

Via Benzinga

The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review ↗

December 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...

Via Benzinga

Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C

December 22, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy

December 22, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies

December 21, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail ↗

December 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...

Via Benzinga

Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease

December 20, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout

December 20, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022 ↗

December 14, 2021

Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ...

Via Benzinga

Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1

December 14, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Workboat Indexes

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

Maritime Throwdown, We Work the Waterways form workforce partnership

Trump budget for maritime programs criticized

Delfin takes $5 billion FID on first US FLNG vessel

Barge demand strengthening, but questions remain